Glaukos breaks ground on new R&D, manufacturing facility in Alabama

Glaukos (GKOS) celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. “We are proud to expand our U.S. footprint with the development of this new state-of-the-art facility to augment our current infrastructure and support our long-term growth plans, underscoring our commitment to American manufacturing and the critical role it plays in advancing healthcare innovation,” said Thomas Burns, Glaukos chairman and chief executive officer. “After evaluating over 100 potential sites worldwide, we ultimately chose Huntsville for its strong talent base and vibrant business climate. We appreciate our new partnership with the City of Huntsville and look forward to the ophthalmic innovations that will emerge from this strategic expansion as we continue advancing our mission to transform vision therapies for patients living with chronic eye diseases.” The agreement includes the development of a new 200,000 square-foot R&D and manufacturing facility to be built on 25 acres in Cummings Research Park, with an option for an additional 15 acres for future expansion. The multi-year project carries a planned capital expenditure of more than $80 million and is expected to bring more than 150 full-time jobs to the region. Glaukos’ new facility is expected to be completed by 2030.